Pharma

Your Article Summary

See Latest Articles

Antigenics Reports First Quarter 2009 Financial Results
Antigenics, 05/28/09

Antigenics Inc. reported results for the quarter ended March 2009. The company incurred a net loss attributable to common stockholders of $9.7 million, or $0.14 per share, basic and diluted, for the first quarter of 2009, compared with a net loss attributable to common stockholders in the first quarter of 2008 of $11.6 million, or $0.21 per share, basic and diluted. The company's net cash burn for the three months ended March 2009 and 2008 was $9.8 million and $9.4 million, respectively. The 2009 results reflect, among other things, the company's continued focus on supporting Oncophage in Europe and Russia. Cash, cash equivalents and short-term investments amounted to $24.6 million as of March 31, 2009.

Today in Financial Reports...keeping you current

Receive free subspecialty "5-minute updates" via email

Ultrasound, nuc med on the upswing
Canadian Healthcare Technology, 10/16/09

Explaining Innovation
PharmExec, 10/16/09

Nabi Biopharmaceuticals Completes Sale of PentaStaph to GlaxoSmithKline PLC
Nabi Biopharmaceuticals, 11/05/09

See All of Financial Reports